PLIANT THERAPEUTICS INC (PLRX) Stock Price, Quote, News and Overview
NASDAQ:PLRX - Nasdaq - US7291391057 - Common Stock - Currency: USD
PLRX Quote, Performance and Key Statistics
3.01
+0.01 (+0.33%)
The current stock price of PLRX is 3.01 USD. In the past month the price decreased by -72.44%. In the past year, price decreased by -81.68%.
PLRX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.16 | 828.87B | ||
| JNJ | JOHNSON & JOHNSON | 15.98 | 384.45B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 26.17 | 371.73B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.65 | 231.22B | ||
| MRK | MERCK & CO. INC. | 11.48 | 221.80B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.52 | 211.95B | ||
| PFE | PFIZER INC | 8.33 | 146.78B | ||
| SNY | SANOFI-ADR | 13.53 | 135.71B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.94 | 113.15B | ||
| GSK | GSK PLC-SPON ADR | 7.88 | 75.42B | ||
| ZTS | ZOETIS INC | 26.59 | 71.02B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.5 | 43.94B |
Related stock screener links
About PLRX
Company Profile
Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. The company is headquartered in South San Francisco, California and currently employs 158 full-time employees. The company went IPO on 2020-06-03. The firm is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The firm has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. The company has also developed PLN-1474, a small molecule, selective inhibitor of αvß1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. The company has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. The firm has a preclinical program, PLN-101325, targeting muscular dystrophies.
Company Info
PLIANT THERAPEUTICS INC
331 Oyster Point Boulevard
South San Francisco CALIFORNIA 94080 US
CEO: Bernard Coulie
Employees: 166
Company Website: https://pliantrx.com/
Investor Relations: https://ir.pliantrx.com/
Phone: 16504816770
PLIANT THERAPEUTICS INC / PLRX FAQ
What is the stock price of PLIANT THERAPEUTICS INC today?
The current stock price of PLRX is 3.01 USD. The price increased by 0.33% in the last trading session.
What is the ticker symbol for PLIANT THERAPEUTICS INC stock?
The exchange symbol of PLIANT THERAPEUTICS INC is PLRX and it is listed on the Nasdaq exchange.
On which exchange is PLRX stock listed?
PLRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PLIANT THERAPEUTICS INC stock?
19 analysts have analysed PLRX and the average price target is 40.29 USD. This implies a price increase of 1238.54% is expected in the next year compared to the current price of 3.01. Check the PLIANT THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PLIANT THERAPEUTICS INC worth?
PLIANT THERAPEUTICS INC (PLRX) has a market capitalization of 183.16M USD. This makes PLRX a Micro Cap stock.
How many employees does PLIANT THERAPEUTICS INC have?
PLIANT THERAPEUTICS INC (PLRX) currently has 166 employees.
Is PLIANT THERAPEUTICS INC (PLRX) expected to grow?
The Revenue of PLIANT THERAPEUTICS INC (PLRX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the PLRX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PLIANT THERAPEUTICS INC (PLRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PLRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PLRX, evaluating the profitability, health, valuation and growth aspects
- PLIANT THERAPEUTICS INC (PLRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PLIANT THERAPEUTICS INC (PLRX) Sales and EPS estimates to see what analysts future expectations are.
- PLIANT THERAPEUTICS INC (PLRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PLIANT THERAPEUTICS INC (PLRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- PLIANT THERAPEUTICS INC (PLRX) Stock Chart to make your own analysis
- PLIANT THERAPEUTICS INC (PLRX) Latest news and press-releases to stay up to date.
Does PLIANT THERAPEUTICS INC (PLRX) stock pay dividends?
PLRX does not pay a dividend.
When does PLIANT THERAPEUTICS INC (PLRX) report earnings?
PLIANT THERAPEUTICS INC (PLRX) will report earnings on 2025-03-04, after the market close.
What is the Price/Earnings (PE) ratio of PLIANT THERAPEUTICS INC (PLRX)?
PLIANT THERAPEUTICS INC (PLRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.34).
What is the Short Interest ratio of PLIANT THERAPEUTICS INC (PLRX) stock?
The outstanding short interest for PLIANT THERAPEUTICS INC (PLRX) is 12.31% of its float. Check the ownership tab for more information on the PLRX short interest.
PLRX Technical Analysis
PLRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PLRX. While PLRX seems to be doing ok healthwise, there are quite some concerns on its profitability.
PLRX Financial Highlights
Over the last trailing twelve months PLRX reported a non-GAAP Earnings per Share(EPS) of -3.34. The EPS decreased by -19.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.25% | ||
| ROE | -58.32% | ||
| Debt/Equity | 0.09 |
PLRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to PLRX. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of -34.25% and a revenue growth -100% for PLRX